Creative Rationale: Our second campaign is the global launch campaign for Tarceva, developed for Genentech/Roche Pharmaceuticals. The campaign, launched in 2005, was designed to communicate two critical features of the brand.

Tarceva® is approved in the European Union, United States and more than 100 other countries for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations. 2,3

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. [4] Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has ...

2024年10月12日 · 厄洛替尼（英语： erlotinib ）以Tarceva（中文译名"得舒缓"或"特罗凯"）等品牌于市面销售，是一种用于治疗 非小细胞肺癌 （ 英语 ： non-small-cell lung cancer ） （NSCLC）和胰脏癌的药物。

On October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer...

“[B]ecause the Tarceva hourglass is positioned on its side, it appears that the sand in the upper half is no longer flowing down to the lower half where the cancer patient and child are located. This presentation strongly suggests that time is standing still for the cancer patient because of Tarceva therapy.

2023年5月25日 · Tarceva (erlotinib) is a cancer chemotherapy medication used in the treatment of non-small cell lung cancer (NSCLC) or pancreatic cancer. What Are Side Effects of Tarceva? Tarceva may cause serious side effects including: Get medical help right away, if you have any of the symptoms listed above. Common side effects of Tarceva include:

Tarceva is a cancer medicine used in non‑small-cell lung cancer (NSCLC) that is advanced (the cancer has started to spread) or metastatic (it has already spread to other parts of the body). It is used for: patients with EGFR activating mutations whose disease is …

Genentech has multiple medicines for serious and life-threatening medical conditions. Access information and resources on each of our medicines.

Erlotinib is a standard of care treatment for locally advanced or metastatic EGFR mutation-positive (Mut+) NSCLC. Erlotinib is recommended by all major international clinical guidelines (including ESMO 1, NCCN 2 and CSCO 3) for the first-line treatment of NSCLC with locally advanced or metastatic EGFR activating mutations.